Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of PLX038 in Primary CNS Tumors
NCT06161519Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Nov 2028
- Modality
- Polymer-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PLX038 in glioma, medulloblastoma, ependymoma and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase II Dose at 42 days and Efficacy of PLX038 at RP2D at 5 years. Started Jan 2024; status: recruiting.
02
Drugs
PLX038
03
Conditions
gliomamedulloblastomaependymomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT06161519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161519.